Recent MIRA News
- MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog • PR Newswire (US) • 05/21/2024 12:45:00 PM
- Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog • PR Newswire (US) • 05/20/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:31:03 PM
- Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission • PR Newswire (US) • 04/02/2024 12:00:00 PM
- MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor • PR Newswire (US) • 03/21/2024 03:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:45:16 PM
- MIRA Pharmaceuticals Provides Corporate Update • PR Newswire (US) • 02/05/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:30:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/28/2023 05:15:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 10:33:10 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/27/2023 10:27:24 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/18/2023 09:50:37 PM
- MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations • PR Newswire (US) • 12/04/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 10:00:35 PM
- MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% • PR Newswire (US) • 11/29/2023 01:00:00 PM
- MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time • PR Newswire (US) • 11/21/2023 03:42:00 PM
- MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a • PR Newswire (US) • 11/21/2023 03:09:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/20/2023 09:18:46 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 01:10:31 PM
- MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 • PR Newswire (US) • 11/20/2023 01:00:00 PM
- MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot • PR Newswire (US) • 09/18/2023 12:30:00 PM
- MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts • PR Newswire (US) • 09/05/2023 12:31:00 PM
- MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit • PR Newswire (US) • 08/31/2023 12:31:00 PM
- MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time • PR Newswire (US) • 08/29/2023 03:39:00 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM